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Abstract: Parietaria pollen is the most important cause of pollen allergies in the Mediterranean
area, as Parietaria is widespread in this region. Many issues are associated with Parietaria allergy,
including the duration of the pollen season (many doctors in fact believe that it lasts throughout the
year), pollen load (which seems to be increasing over time), the impact of age (on IgE production
and symptom severity), inflammatory changes (after pollen exposure), and the choice of allergen
immunotherapy (AIT). In addition, molecular diagnostics allows for the defining of a correct
diagnosis, differentiating between mere sensitization and true allergy. This review considers these
topics and will hopefully help the allergist in clinical practice. Parietaria allergy is an intriguing
challenge for the allergist in clinical practice, but it may be adequately managed by knowing the
peculiarities of respective territories and the clinical characteristics of each patient.
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1. Introduction
Parietaria allergy is a frequent manifestation of pollen allergy arising mainly in the Mediterranean
area [1]. Parietaria allergy has some peculiar characteristics, including relevant epidemiological impact
and long duration of symptoms (caused by the pollination period consistently being long-lasting).
Asthma and rhinitis are frequently associated with the allergy, and have been treated with allergen
immunotherapy for a long time [2,3]. With regard to these issues, it is important that this review
present and discuss the most relevant clinical and therapeutic aspects.
2. Parietaria Pollen Impact on Allergy Patients
It is well known that the Parietaria plant is a weed that is widespread in the Mediterranean area,
and that many people are allergic to it: it is responsible for up to 25–30% of all allergy patients [1].
Parietaria belongs to the Urticaceae family. Although many species of it exist, the most relevant are
P. officinalis and P. judaica, if concerned with allergy pathogenesis. The term “parietaria” derives from
the Latin word paries, meaning wall, as it easily grows in the shade of old walls. Another name for the
plant is Parietaria “vetriola”, as it has historically been used for cleaning glass bottles.
The Parietaria pollen is small, and its mean diameter is measured in microns (more than PM10).
As a consequence, only some grains can penetrate to the trachea, and none are able to reach the
terminal bronchioles. Thus, a high frequency of asthma may be induced by bronchial inflammation
deriving from inflammatory events occurring in the upper airways, as well as by other immunological
mechanisms (such as, probably, paucimicronic particles carrying allergens). Indeed, patients allergic to
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Parietaria also frequently suffer from asthma [2]. However, a crucial issue which should be noted is
that when atmospheric pollen grains are identified under an optical microscope, Parietaria pollen is
not distinguishable from the pollen of most species of the genus Urtica. Consequently, these pollen
grains may be identified as the pollen type Urticaceae. This point may suggest a need for caution in
interpreting data reported in many studies, as overestimates of the number of Parietaria pollen grains
may persist.
Furthermore, there is agreement regarding the concept that the prevalence of allergic disorders is
growing. Because of this, many pathogenic theories have been hypothesized, including one positing
an increase in pollen load. A five year aerobiological study, conducted from 1984 to 1988, indicated that
Parietaria allergy is a noticeable issue in Italy, unlike in most other European countries, due to the
duration and the quantity of pollen production [3]. More recently, a study demonstrated that the
Parietaria season has tended to be prolonged, and its pollen count has tended to increase over time [4].
A second study took place over a 30-year period in the same geographic region [5]. Its main outcomes
provided evidence that sensitization prevalence to Parietaria did not change as significantly as Parietaria
pollen counts over time, but that the Parietaria pollen season was prolonged, a fact that is due to
climatic and environmental change over the same period.
In this regard, the Parietaria pollination season may be rather long, and there is a popular belief
that the symptoms for Parietaria allergy may be present for the whole year. This belief may have a
practical implication for allergen immunotherapy (AIT) prescription. In fact, many doctors prefer to
prescribe AIT for Parietaria allergy patients using a continuous schedule, while usually prescribing
pre-co-seasonal AIT courses for allergies to other pollens. Though dependent on climatic factors,
the actual duration of Parietaria pollen season is never perennial. Indeed, the Parietaria pollen season
usually has two peaks: a main peak during spring and a second during early autumn. In autumn,
there is a low peak in comparison to the very high concentrations observed in spring. A recent study
addressed the assessment of the actual duration of the Parietaria pollen season in Italy, and was
undertaken over a 10-year observation period [6]. Its findings show that Parietaria pollination lasts
6–7 months on average, with two main peaks seen: an important peak during mid-spring and a lower
peak during early fall. However, there is remarkable variation within different geographic areas.
These differences are obviously dependent on the climatic characteristics of each region. Interestingly,
these outcomes are substantially consistent with those found in previous surveys.
The seasonality of Parietaria pollen was confirmed by a study that demonstrated a clear association
between pollen exposure and nasal inflammation in patients allergic to Parietaria [7]. This phenomenon
can be easily interpreted by considering the idea that allergic inflammation is closely dependent on
pollen exposure [8]. In fact, the duration of nasal allergic inflammation typically mirrors the duration
of the pollen season for patients with Parietaria allergy.
This concept may have practical consequences for approaches to the treatment of patients with
Parietaria allergy, mainly with regard to the AIT schedule. In relation to this, two studies have recently
been published. The first study demonstrated that a cycle schedule was as effective as a continuous
course [9]. The second confirmed that a single pre-co-seasonal sublingual immunotherapy (SLIT)
Parietaria course could be sufficient to reduce symptom severity and medication use [10].
Another interesting issue is the impact of age on allergen-specific IgE production. Some studies
conducted in Italy have confirmed that sensitization to Parietaria pollen does not significantly decrease
with age [11,12]. In other words, IgE production due to Parietaria pollen persists until late age.
This fact has a clinical consequence: it has been reported that the severity of allergic symptoms is
slightly affected by age for Parietaria allergy patients, whereas patients with house dust mite allergies
frequently perceive less severe symptoms after 40 years of age, as mite sensitization significantly
diminishes after this age [13].
Molecular diagnostics is a crucial step in the work-up of allergy patients, mainly with regard
to AIT prescription [14]. Defining the molecular pattern of sensitization allows for discrimination
between genuine sensitization and that which is spurious, thus avoiding ineffective AIT prescriptions.
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Additionally, serum IgE level assessment may be useful for differentiating true allergies from mere
sensitization [15]. There is evidence that measurement of the level of IgE to Par j 2 allows for the
recognition of allergic subjects [16].
3. Allergen Immunotherapy for Parietaria Allergy
The first controlled trial on the efficacy and safety of subcutaneous immunotherapy (SCIT) dates
back to 1994. In this trial, 18 patients with rhinoconjunctivitis caused by Parietaria pollen were treated
with a partially purified alginate-conjugated extract of P. judaica, or a placebo. During the Parietaria
pollen season, actively treated patients had significantly lower nasal symptom/medication scores
and significant decreases in specific, nasal and conjunctival reactivity to the Parietaria extract [17].
A year later, the first double-blind trial on the effects of SLIT on Parietaria-induced rhinitis was
published; it included 31 patients randomized to active or placebo treatment. When comparing data
obtained before and after a 10-month period of treatment, it can be observed that actively treated
patients had significantly lower medication scores during maximum Parietaria pollen counts, as well
as a significant decrease in nasal reactivity by the end of the study [18]. Indeed, these controlled
studies were preceded by a trial on 38 patients allergic to Parietaria who were treated with local nasal
immunotherapy (LNIT) or a placebo. Positive outcomes were reported for medication scores (but not
symptom scores) and nasal reactivity to Parietaria [19]. However, this route of administration is no
longer used because of the high rate of local nasal reactions to treatment. As for SCIT and SLIT,
several additional controlled studies were performed in the following years. Tables 1 and 2 summarize
the main observations from trials on SCIT [20–26] and on SLIT [27–33]. Similarly to what has been
done for the most important allergens in recent years, the search for better quality immunotherapy
products has resulted in a series of scientific publications, the results of which are summarized
here. One important aspect regards the safety and tolerability of the two routes of administration.
For SLIT the available data indicate a greater frequency of local reactions in the oral cavity, but not
of systemic reactions [34]. Regarding SCIT, a prospective 3-year study on 510 patients treated with
mono-phosphoril lipid-associated allergoids as adjuvant reported a frequency of systemic reactions
(none of them serious) of 1.37% [35]. However, severe reactions cannot be ruled out, especially if
ultra-rush patterns are used [36]. Approaches proposed in recent years to improve both the efficacy
and safety of Parietaria pollen immunotherapy consist of using innovative materials but also the
development of techniques able to increase diagnostic precision and therefore to improve prescription
appropriateness. With regard to the first approach, hybridization techniques employing genetic
engineering using fragments of the two major allergens of P. judaica (Par j 1 and Par j 2) allowed for
the obtaining of proteins with reduced allergenic activity, which were associated with reduced skin
reactivity [37]. In an Italian experimental study, recombinant molecules with variants of Par j 1 and Par
j 2, obtained by genetic engineering, proved to be markedly less reactive while retaining the ability
to stimulate T cells and the production of IgG antibodies in a similar way to the natural extract of
pollen [38]. Another promising technology may be found in nanoparticles, which can be used as
protein vehicles. Using solid lipid nanoparticles, the recombinant molecule of Par j 2 has demonstrated
high safety in vitro [39]. The same group of researchers also studied a nano-aggregated allergenic
copolymer, which likewise demonstrated safe application in human tissues, in addition to an ability
not to alter the capacity to cross-link with specific IgE and therefore not to interfere with the activity
of allergen-induced biology [40]. Finally, a further form of hybridization of Par j 1, Par j 2, and their
isoforms has shown that the recombinant hetero-dimeric Par j heterodimer (PjED), which may be
obtained from the shorter isoform of Par j 1 allergen, induces the synthesis of IgG1. IgG1 is able to bind
to all major allergic isoforms of Parietaria, representing a promising candidate for immunotherapy [41].
It must be stated that all these forms of immunotherapy have yet to reach the development phase for
possible use in clinical practice.
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Table 1. Controlled trials on subcutaneous immunotherapy with Parietaria extracts.
Author, Year [Ref] Study Population Issue Addressed Results
D’Amato et al., 1995 [20] 20 adult pts Efficacy and safety Significant decrease of nasal symptoms, comparable incidence of systemicreactions in active and placebo treatment
Tari et al., 1997 [21] 40 adult pts Efficacy and safety Improvement in nasal inspiratory peak flow, low incidence of side effects
Ariano et al., 1999 [26] 25 patients of all ages Efficacy and safety Significant reduction of symptom-medication scores (SMS), decrease of sIgEand increase of sIgG4; no important side effects
Garcia-Selles et al., 2003 [22] 30 adult pts Efficacy and safety Significant difference in SMS in actively vs. placebo treated; no side effects.
Crimi et al., 2004 [23] 30 adult pts Efficacy and effect on bronchialhyper-responsiveness (BHR) Significant difference in SMS in actively vs. placebo treated; no change in BHR
Polosa et al., 2004 [24] 30 adult pts Efficacy, effect on BHR andsputum eosinophils.
Significant difference in SMS in actively vs. placebo treated; no change in BHR
and sputum eosinophils.
Ferrer et al., 2005 [25] 42 adult pts Efficacy and safety Sustained decrease in SMS in actively treated; no side effects.
Table 2. Controlled trials on sublingual immunotherapy (SLIT) with Parietaria extracts.
Author, Year [Ref] Study Population Issue Addressed Results
Purello D’Ambrosio et al., 1996 [27] 40 adult pts Efficacy and safety Significantly lower SMS in SLIT treated; no side effects
Passalacqua et al., 1999 [28] 30 adult pts Efficacy and safety Significant reduction of symptom score and drug intake in the activegroup; no side effects
Purello D’Ambrosio et al., 1999 [29] 30 adult pts Efficacy and safety Significantly lower symptom and drug scores in SLIT treatment;no side effects
La Rosa et al., 1999 [30] 41 children Efficacy and safety
Significant reduction in symptom but not in medications scores;
increase in the threshold dose for conjunctival allergen provocation
test; no side effects
Pajno et al., 2003 [31] 38 children Comparison of efficacy of SLIT and fluticasonein Parietaria induced asthma
Equal efficacy of SLIT and fluticasone, only SLIT efficacious also
in rhinitis
Pajno et al., 2004 [32] 30 children Effect on seasonal BHR. Abrogation of seasonal BHR in actively treated children
D’Anneo et al., 2008 [33] 65 adult pts Efficacy and effect on BHR of two SLIT dosagescompared to drug therapy; safety
Significant improvement in symptoms, drug use and BHR in both
SLIT group; no side effects
SMS: Symptom mean score; BHR: Bronchial Hyperreactivity.
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The other important field of application is represented by the advanced techniques available for
precision diagnosis. In 2007, the group Valenta suggested that molecular diagnostics (also referred to
as component-resolved diagnosis (CRD), or simply molecular diagnostics, as previously reported) can
be particularly useful with regard to pollinosis from plants such as Parietaria, which often affects
polysensitized patients. With these patients, it is essential to identify the specific molecules of
the respective pollen, distinguishing them from molecules of other pollens and facilitating a more
appropriate prescription of AIT [42]. It has been reported that the presence in subjects with positive
allergy tests of specific IgE to Par j 2 makes it possible to distinguish clinical allergies from simple
sensitization [43]. This is particularly relevant from a clinical point of view, as it allows for the
accurate obtaining of an appropriate AIT prescription. Another molecular allergy study on individuals
with positive allergy testing for Parietaria has shown that the specific culpability of Urtica dioica
(an Urticaceae species which is cross-reactive with Parietaria), which contains species-specific allergens
such as osmotin (a taumatin-like protein) and pectin-esterase, can be assessed by CRD, thus avoiding
the prescription of immunotherapy with a low probability of success [44]. Finally, one study has
demonstrated the usefulness of the basophil activation test (BAT) in patients sensitized to Parietaria.
In particular, among the different activation markers, CD203c appeared to be related to the presence of
symptoms, allowing for the identification of in vitro patients with asymptomatic sensitization [45].
For patients treated with immunotherapy, serum levels of interleukin 9 (IL-9) have proven useful
for indicating treatment efficacy. In fact, when comparing patients allergic to Parietaria who were
treated with SLIT to those treated with drugs, significantly lower levels were found in patients treated
with SLIT [46]. This is particularly important with regard to clinical practice because there is a need to
measure biomarkers which are potentially able to a priori select responders to AIT and to evaluate AIT
effectiveness [47,48].
Studies defined as “real-life”, due to their employment of common clinical practice patients
and not patients chosen via the rigid and selective methods of double-blind placebo-controlled
trials, provide data of great value to physicians interested in AIT. In one study of patients with
mild asthma, a cycle of SCIT based on four injections of Parietaria extract with mono-phosphoryl lipid
as adjuvant obtained an improvement in asthma control, and was measured using the questionnaire
“Asthma control test” [49]. In another real-life study of high dose SLIT with standardized extracts
(Staloral 300IR) in patients with various types of pollinosis, P. judaica was the most widely used,
along with grasses and Cupressaceae. Patients suffered from severe allergic rhinitis (in 55% of cases
there was mild asthma) and were evaluated after 12 and 36 months of treatment by considering their
total score of nasal symptoms and drug use, and, in patients with asthma, asthma symptoms and
consumption of asthma drugs. There were statistically significant differences from baseline values
for rhinitis symptoms (p < 0.041), consumption of drugs for rhinitis (p < 0.0162), asthmatic symptoms
(p < 0.0162), and consumption of asthma drugs (p < 0.0005) [50].
Studies have also been undertaken on two important aspects of immunotherapy: effects on
quality of life, and pharmaco-economic aspects. One study prospectively evaluated 167 polysensitized
patients, in which the most common causes of sensitization were grass pollen, Parietaria pollen and
dust mites. Quality of life was measured using the “Rhinoconjunctivitis quality of life” questionnaire,
which was taken once before starting and once after a year of treatment. SLIT was performed using a
single extract for 123 patients (73.6%), two extracts for 31 patients (18.6%) and more than two extracts
for only 13 patients (7.8%). Quality of life improved significantly (p < 0.01 compared to the baseline) in
all cases [51]. Another pharmaco-economic study examined 30 patients who suffered from rhinitis
and asthma due to Parietaria, 20 of whom were treated with SCIT with an extract of Parietaria judaica
(Alustal, Stallergénes) and 10 of whom were treated with antiallergic drugs. All patients were evaluated
before starting and then annually for a duration of six years, based on allergic symptoms during the
Parietaria pollination period and the consumption of drugs. A significant difference was observed in
favor of immunotherapy, with a reduction in treatment costs of approximately 15% in the second year
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and 48% in the third year. Three years after SCIT was stopped the reduction in costs reached 80%,
with a net saving for each patient that corresponded to €623 [52].
Another interesting aspect is the tolerability of SCIT: a very recent study demonstrated that
Parietaria judaica subcutaneous immunotherapy (Allergovac® depot ROXALL Medicina España),
with an abbreviated up-dosing scheme, showed an adequate safety and tolerability profile and induced
preliminary efficacy changes [53]. This indicates that a rapid schedule may be safe and well tolerated.
Finally, a new therapeutic strategy approach may be the design of standardized recombinant
hypoallergenic derivatives which can reduce allergic adverse events. A recent study using mice
demonstrated the capability of an engineered hybrid, based on the disruption of disulphide bonds
in the allergen molecule, to modulate pre-existing sensitization towards a protective immune
response [54]. These findings could represent a new model applicable to other allergen molecules
belonging to the lipid transfer protein family.
4. Conclusive Remarks
Parietaria allergy is very common in the Mediterranean area, especially in Italy. It has specific
peculiarities, mainly concerning the duration of its pollen season and the persistence of symptoms
in elderly people. AIT is usually effective and new potential treatment schedules could possibly be
performed. However, as AIT is a perfect example of Personalized Medicine, it is fundamental to use
a pragmatic approach based on Precision Medicine in order to define specific biomarkers of clinical
utility for the management of AIT, as has been recently pointed out [55].
Moreover, there is a body of evidence indicating that many factors are involved in the increased
propensity of people to overreact to previously innocuous and tolerated antigens. These factors
include environmental influence, developmental plasticity origins, and the hygiene hypothesis.
It is well known that pollution is a significant factor that can modify climate characteristics,
which in turn may significantly affect the vegetable kingdom, and critically, Parietaria pollen
production [56,57]. The environment can also play a role as phenotype inducer so that a single
genotype can become able to express an alternative appropriate phenotype, as a consequence of
environmental variation [58]. This phenomenon is defined as developmental plasticity, which is often
heritable, and may evolve under selective mechanisms [59]. Hence, people can produce integrated,
adaptive, and environment-specific phenotypes as natural evolution resulting from changes in global
climate occurs [60]. In this regard, the hygiene hypothesis has produced a unanimous body of
evidence which explains the allergy epidemics. This theory was proposed initially by Strachan who
speculated that exposure to frequent infections in large families could be a protective factor for allergy
onset [61]. The hygiene hypothesis has evolved toward a more contemporary “biodiversity hypothesis”
that looks beyond the effect of both infections and single microbes to the potential protective effect
of gut colonization with diverse environmental microflora; the term “microbiota hypothesis” has
been proposed [62]. Overall, environmental factors, developmental plasticity, and the microbiota
hypothesis may have modified the immune response to allergens from a tolerance condition to
IgE-mediated hypersensitivity.
In conclusion, Parietaria allergy is an intriguing challenge for the allergist in clinical practice, but it
may be adequately managed by knowing the peculiarities of the respective territories and the clinical
characteristics of each patient.
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selected air pollutants and meteorological parameters. Environ. Sci. Pollut. Res. Int. 2016, 23, 10072–10079.
[CrossRef] [PubMed]
Medicina 2018, 54, 106 10 of 10
57. D’Amato, G.; Vitale, C.; Lanza, M.; Molino, A.; D’Amato, M. Climate change, air pollution, and allergic
respiratory diseases: An update. Curr. Opin. Allergy Clin. Immunol. 2016, 16, 434.
58. Gomez-Mestre, I.; Jovani, R. A heuristic model on the role of plasticity in adaptive evolution:
Plasticity increases adaptation, population viability and genetic variation. Proc. R. Soc. B 2013, 280, 20131869.
[CrossRef] [PubMed]
59. Scheiner, S.M.; Barfield, M.; Holt, R.D. The genetics of phenotypic plasticity. XI. Joint evolution of plasticity
and dispersal rate. Ecol. Evol. 2012, 2, 2027–2039. [CrossRef]
60. Auld, J.R.; Agrawal, A.A.; Relyea, R.A. Re-evaluating the costs and limits of adpatative phenotypic plasticity.
Proc. R. Soc. B 2010, 277, 503–511. [CrossRef]
61. Strachan, D.P. Hay fever, hygiene, and household size. BMJ 1989, 299, 12591260. [CrossRef]
62. Sokolowska, M.; Akdis, C.A. Highlights in immune response, microbiome and precision medicine in allergic
disease and asthma. Curr. Opin. Immunol. 2017, 48, iv–ix. [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
